ACADIA Pharmaceuticals Reviews

Recommend to a friend
Approve of CEO
ACADIA Pharmaceuticals CEO and Director Uli Hacksell
Uli Hacksell
1 Rating
  • Acadia - pays ok, but will fire you.

    • Work/Life Balance
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Research Scientist in Malmö, Skåne (Sweden)
    Former Employee - Research Scientist in Malmö, Skåne (Sweden)

    I worked at ACADIA Pharmaceuticals

    Doesn't Recommend
    Disapproves of CEO
    Doesn't Recommend
    Disapproves of CEO


    Normally a good salary can be obtained. I feel that a good work-private time can be achieved. A fair ammount of freedom can at times be given.


    Everything is ruled by one director. Evebn if an attempt is beeing made to solve some difficult issues this attempt, and with it several years of research can be thrown away. Teh people in charge do not look upon the data in a scientific, neutral way. Instead they are bias and take into acount the data that supports their theory. The senior management tend to be a little bit too full of themselves. Getting fired.

    Advice to Management

    A more modest aproach. Actually sselling or partnering project before moving them into phase 2. One person should not be in charge for the research.

ACADIA Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters San Diego, CA
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (ACAD)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year

ACADIA Pharmaceuticals develops small molecule drugs for the treatment of central nervous system disorders. The biopharmaceutical company's most advanced compound, pimavanserin, is in clinical trials as a treatment for Parkinson's disease psychosis, which occurs in up to 40% of Parkinson's patients. Two other clinical-stage candidates are being developed in collaboration with Allergan to treat patients with chronic pain (AGN-XX/YY) and glaucoma (AC-262271). A preclinical candidate, AM-831, a compound that holds the potential for a new class of antipsychotic ... More

Work at ACADIA Pharmaceuticals? Share Your Experiences

ACADIA Pharmaceuticals

Click to Rate